Repurposed asthma drug shows blood sugar improvement among some diabetics

July 5, 2017, University of California - San Diego
Fat cells outlined in blue with inflammatory cells (inflammation) in green. Credit: UC San Diego Health

After 12 weeks of taking an anti-asthma drug, a subset of patients with type 2 diabetes showed a clinically significant reduction in blood glucose during a randomized, double blind, placebo-controlled clinical trial, report University of California San Diego School of Medicine and University of Michigan researchers.

In a paper publishing July 5 in Cell Metabolism, a team led by Alan Saltiel, PhD, director of the UC San Diego Institute for Diabetes and Metabolic Health, and Elif Oral, MD, director of the MEND Obesity and Metabolic Disorder Program at the University of Michigan, along with scientists at the Salk Institute for Biological Sciences, identified a molecular signature in who responded to amlexanox, an anti-inflammatory and anti-allergic drug used to treat asthma that was developed in the 1980s in Japan. The discovery is not ready for the clinic, but it does reveal a potential new therapeutic approach for treating type 2 diabetes.

"When we looked at the drug-treated group we saw a bimodal distribution, that is, there were some responders and some non-responders. We didn't understand why, so we did a molecular analysis from biopsies of fat cells we took from patients at the beginning and end of the study," said Saltiel.

"In the responder group, the level of inflammation in fat was higher than in the non-responder group at the beginning of the study, indicating that there is something about inflammation that predisposes a person to respond. And, what was really amazing was that there were more than 1,100 gene changes that occurred exclusively in the responders."

Amlexanox is an inhibitor of two enzymes, IKKε and TBK1. In previous studies, Saltiel and team had discovered that these two enzymes are induced in obese mice, causing a drop in energy expenditure or reduction in calories burned. This prompted them to look for inhibitors of these enzymes by screening a library of 150,000 chemicals. They found amlexanox. Giving the inhibitor caused them to lose weight, while their sensitivity to insulin increased, improving their diabetes and .

The human trial revealed that gene changes that occurred in the mouse model also happened in the human responder group. Blood sugar in the clinical trial patients went down as genes involved in the expenditure of energy changed.

The proof of concept trial began with an un-blinded safety trial of six patients. It was followed by a controlled trial of 42 obese patients with type 2 diabetes. Half of the patients were randomized to a placebo group while the other half received amlexanox for three months. Blood sugar, insulin sensitivity, weight and liver fat were measured. A biopsy of fat cells from each patient's midsection was taken before and after the trial to measure changes in gene expression.

"The most exciting part of this is that we have a new drug that has never been studied before," said Saltiel. "It's a new mechanism for a diabetes and fatty liver drug. It's promising, but there are a lot of questions that need to be answered still."

Among them: Which gene changes are the most important to target? What's the right drug dosage? What time of day should it be administered? How often should patients take the drug? What other drug combinations can be used with amlexanox? Can the percentage of responders be increased? Will the beneficial effects of the drug be sustained for a longer time?

One-third of the participants in the blinded study responded. Among responders with nonalcoholic fatty liver disease, an improvement was also seen.

Saltiel said his lab at UC San Diego School of Medicine plans to dive deeper into the gene changes to better understand which are most important, which affect liver fat, which translate into changes in levels and more. He is planning a new human clinical trial with colleagues at Michigan.

"We're planning a new study to look at whether we can stratify patients who are likely to respond based on the degree of underlying inflammation," said Saltiel. "A second study will look at a combination with another that we think will be particularly effective."

Saltiel started this work while serving as director of the Life Sciences Institute (LSI) at the University of Michigan; the chemical screen was conducted at the LSI's Center for Chemical Genomics; the clinical trial was conducted at the University of Michigan. Analysis of the data and biopsy samples occurred at UC San Diego and the Salk Institute.

Explore further: Old drug may point the way to new treatments for diabetes and obesity

More information: Cell Metabolism (2017). DOI: 10.1016/j.cmet.2017.06.006

Related Stories

Old drug may point the way to new treatments for diabetes and obesity

February 10, 2013
Researchers at the University of Michigan's Life Sciences Institute have found that amlexanox, an off-patent drug currently prescribed for the treatment of asthma and other uses, also reverses obesity, diabetes and fatty ...

Breaking the cycle of obesity, inflammation and disease

December 19, 2013
Researchers at University of Michigan have illuminated an aspect of how the metabolic system breaks down in obesity. The findings provide additional evidence that a drug entering clinical trials at the university could reverse ...

Researchers uncover more clues to how drug reverses obesity, diabetes, fatty liver disease

January 12, 2015
Researchers at the University of Michigan have identified how a promising drug in clinical trials for the treatment of obesity and related metabolic disorders improves the metabolism of sugar by generating a new signal between ...

MEND researchers are ready for human trials of an obesity drug showing dramatic results in mice

June 28, 2013
As sometimes happens in science, a medication used for one thing turns out to be very good for something else.

Diabetes drug trial needs to widen participants to understand full impact of drugs

June 14, 2017
More work needs to be done to examine the real world effects of the commonly prescribed diabetes drug empagliflozin, new research in the journal Diabetes Therapy finds.

Existing diabetes drug shows effectiveness against chronic liver disease

June 21, 2016
Researchers have found that an existing diabetes drug can be used to halt progression of another disease that is a leading cause of liver transplants.

Recommended for you

Study shows drug effectiveness in reducing glucocorticoid-induced bone loss

April 25, 2018
About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect—they induce the bone loss called osteoporosis, ...

Implantable islet cells come with their own oxygen supply

April 25, 2018
Since the 1960s, researchers have been interested in the possibility of treating type 1 diabetes by transplanting islet cells—the pancreatic cells that are responsible for producing insulin when blood glucose concentration ...

Bariatric surgery successes lead to type 2 diabetes treatment

April 24, 2018
Bariatric surgery has long yielded almost immediate health benefits for patients with type 2 diabetes, and new findings on the reasons for remission may be the key to developing drug alternatives to surgery.

Hacking human 'drug trafficking' network could make diabetes treatments more effective

April 23, 2018
Making tiny changes to existing diabetes treatments can alter how they interact with cells, and potentially make the medicines more effective.

Vitamin D deficiency linked to greater risk of diabetes

April 19, 2018
An epidemiological study conducted by researchers at University of California San Diego School of Medicine and Seoul National University suggests that persons deficient in vitamin D may be at much greater risk of developing ...

One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo

April 17, 2018
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.